A citation-based method for searching scientific literature


List of co-cited articles
699 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
29

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
431
27

Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.
Nikita Pozdeyev, Laurie M Gay, Ethan S Sokol, Ryan Hartmaier, Kelsi E Deaver, Stephanie Davis, Jena D French, Pierre Vanden Borre, Daniel V LaBarbera, Aik-Choon Tan,[...]. Clin Cancer Res 2018
139
15

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
750
14

Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes.
Ian Ganly, Vladimir Makarov, Shyamprasad Deraje, YiYu Dong, Ed Reznik, Venkatraman Seshan, Gouri Nanjangud, Stephanie Eng, Promita Bose, Fengshen Kuo,[...]. Cancer Cell 2018
74
18

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
682
13

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Alan L Ho, Ravinder K Grewal, Rebecca Leboeuf, Eric J Sherman, David G Pfister, Desiree Deandreis, Keith S Pentlow, Pat B Zanzonico, Sofia Haque, Somali Gavane,[...]. N Engl J Med 2013
395
13

Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, David Viola, Rossella Elisei, Bela Bendlova, Linwah Yip, Caterina Mian, Federica Vianello, R Michael Tuttle,[...]. JAMA 2013
521
13

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
818
12


Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
Seong-Keun Yoo, Young Shin Song, Eun Kyung Lee, Jinha Hwang, Hwan Hee Kim, Gyeongseo Jung, Young A Kim, Su-Jin Kim, Sun Wook Cho, Jae-Kyung Won,[...]. Nat Commun 2019
53
20

Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.
Raj K Gopal, Kirsten Kübler, Sarah E Calvo, Paz Polak, Dimitri Livitz, Daniel Rosebrock, Peter M Sadow, Braidie Campbell, Samuel E Donovan, Salma Amin,[...]. Cancer Cell 2018
69
15

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Julio C Ricarte-Filho, Mabel Ryder, Dhananjay A Chitale, Michael Rivera, Adriana Heguy, Marc Ladanyi, Manickam Janakiraman, David Solit, Jeffrey A Knauf, R Michael Tuttle,[...]. Cancer Res 2009
345
10

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Marcia S Brose, Maria E Cabanillas, Ezra E W Cohen, Lori J Wirth, Todd Riehl, Huibin Yue, Steven I Sherman, Eric J Sherman. Lancet Oncol 2016
129
10

Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013.
Hyeyeun Lim, Susan S Devesa, Julie A Sosa, David Check, Cari M Kitahara. JAMA 2017
652
10

Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.
Lara A Dunn, Eric J Sherman, Shrujal S Baxi, Vatche Tchekmedyian, Ravinder K Grewal, Steven M Larson, Keith S Pentlow, Sofia Haque, R Michael Tuttle, Mona M Sabra,[...]. J Clin Endocrinol Metab 2019
44
22

BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
364
10

Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors.
Yuri E Nikiforov, Raja R Seethala, Giovanni Tallini, Zubair W Baloch, Fulvio Basolo, Lester D R Thompson, Justine A Barletta, Bruce M Wenig, Abir Al Ghuzlan, Kennichi Kakudo,[...]. JAMA Oncol 2016
703
9

TERT promoter mutations in thyroid cancer.
Rengyun Liu, Mingzhao Xing. Endocr Relat Cancer 2016
166
9

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
292
9

Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.
Seong-Keun Yoo, Seungbok Lee, Su-Jin Kim, Hyeon-Gun Jee, Byoung-Ae Kim, Hyesun Cho, Young Shin Song, Sun Wook Cho, Jae-Kyung Won, Jong-Yeon Shin,[...]. PLoS Genet 2016
130
9

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
C Durante, N Haddy, E Baudin, S Leboulleux, D Hartl, J P Travagli, B Caillou, M Ricard, J D Lumbroso, F De Vathaire,[...]. J Clin Endocrinol Metab 2006
801
9

Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Marina N Nikiforova, Stephanie Mercurio, Abigail I Wald, Michelle Barbi de Moura, Keith Callenberg, Lucas Santana-Santos, William E Gooding, Linwah Yip, Robert L Ferris, Yuri E Nikiforov. Cancer 2018
131
8

Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
Debyani Chakravarty, Elmer Santos, Mabel Ryder, Jeffrey A Knauf, Xiao-Hui Liao, Brian L West, Gideon Bollag, Richard Kolesnick, Tin Htwe Thin, Neal Rosen,[...]. J Clin Invest 2011
199
8

TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
Miguel Melo, Adriana Gaspar da Rocha, Rui Batista, João Vinagre, Maria João Martins, Gracinda Costa, Cristina Ribeiro, Francisco Carrilho, Valeriano Leite, Cláudia Lobo,[...]. J Clin Endocrinol Metab 2017
58
13

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Iñigo Landa, Ian Ganly, Timothy A Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A Ghossein, James A Fagin. J Clin Endocrinol Metab 2013
249
8

Thyroid cancer.
Maria E Cabanillas, David G McFadden, Cosimo Durante. Lancet 2016
370
8

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.
Lori J Wirth, Eric Sherman, Bruce Robinson, Benjamin Solomon, Hyunseok Kang, Jochen Lorch, Francis Worden, Marcia Brose, Jyoti Patel, Sophie Leboulleux,[...]. N Engl J Med 2020
45
17

Selective RET kinase inhibition for patients with RET-altered cancers.
V Subbiah, V Velcheti, B B Tuch, K Ebata, N L Busaidy, M E Cabanillas, L J Wirth, S Stock, S Smith, V Lauriault,[...]. Ann Oncol 2018
131
7

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Vivek Subbiah, Robert J Kreitman, Zev A Wainberg, Jae Yong Cho, Jan H M Schellens, Jean Charles Soria, Patrick Y Wen, Christoph Zielinski, Maria E Cabanillas, Gladys Urbanowitz,[...]. J Clin Oncol 2018
235
7


Biologic and Clinical Perspectives on Thyroid Cancer.
James A Fagin, Samuel A Wells. N Engl J Med 2016
276
7

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
Mingzhao Xing, William H Westra, Ralph P Tufano, Yoram Cohen, Eli Rosenbaum, Kerry J Rhoden, Kathryn A Carson, Vasily Vasko, Alexandr Larin, Giovanni Tallini,[...]. J Clin Endocrinol Metab 2005
676
7

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
188
7

NTRK fusion-positive cancers and TRK inhibitor therapy.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
328
7

The landscape of kinase fusions in cancer.
Nicolas Stransky, Ethan Cerami, Stefanie Schalm, Joseph L Kim, Christoph Lengauer. Nat Commun 2014
466
6

Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.
Maria E Cabanillas, Mabel Ryder, Camilo Jimenez. Endocr Rev 2019
38
15

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
746
6

Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.
James Nagarajah, Mina Le, Jeffrey A Knauf, Giuseppe Ferrandino, Cristina Montero-Conde, Nagavarakishore Pillarsetty, Alexander Bolaender, Christopher Irwin, Gnana Prakasam Krishnamoorthy, Mahesh Saqcena,[...]. J Clin Invest 2016
51
11

Molecular genetics and diagnosis of thyroid cancer.
Yuri E Nikiforov, Marina N Nikiforova. Nat Rev Endocrinol 2011
544
6

Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers.
Julio C Ricarte-Filho, Sheng Li, Maria E R Garcia-Rendueles, Cristina Montero-Conde, Francesca Voza, Jeffrey A Knauf, Adriana Heguy, Agnes Viale, Tetyana Bogdanova, Geraldine A Thomas,[...]. J Clin Invest 2013
117
6

Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Bin Xu, Talia Fuchs, Snjezana Dogan, Iñigo Landa, Nora Katabi, James A Fagin, R Michael Tuttle, Eric Sherman, Anthony J Gill, Ronald Ghossein. Thyroid 2020
19
31

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
6

Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
Mingzhao Xing, Ali S Alzahrani, Kathryn A Carson, Young Kee Shong, Tae Yong Kim, David Viola, Rossella Elisei, Bela Bendlová, Linwah Yip, Caterina Mian,[...]. J Clin Oncol 2015
281
6

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee, Benjamin L Ebert, Michael A Gillette, Amanda Paulovich, Scott L Pomeroy, Todd R Golub, Eric S Lander,[...]. Proc Natl Acad Sci U S A 2005
6

Novel targeted therapies and immunotherapy for advanced thyroid cancers.
George E Naoum, Michael Morkos, Brian Kim, Waleed Arafat. Mol Cancer 2018
59
10

Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
S Michael Rothenberg, David G McFadden, Edwin L Palmer, Gilbert H Daniels, Lori J Wirth. Clin Cancer Res 2015
130
6

Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
John W Kunstman, C Christofer Juhlin, Gerald Goh, Taylor C Brown, Adam Stenman, James M Healy, Jill C Rubinstein, Murim Choi, Nimrod Kiss, Carol Nelson-Williams,[...]. Hum Mol Genet 2015
174
6

Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.
Maria E Cabanillas, Jonas A de Souza, Susan Geyer, Lori J Wirth, Michael E Menefee, Stephen V Liu, Komal Shah, John Wright, Manisha H Shah. J Clin Oncol 2017
53
11

Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
Lindsey M Kelly, Guillermo Barila, Pengyuan Liu, Viktoria N Evdokimova, Sumita Trivedi, Federica Panebianco, Manoj Gandhi, Sally E Carty, Steven P Hodak, Jianhua Luo,[...]. Proc Natl Acad Sci U S A 2014
147
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.